Medtronic is upping the ante in a patent dispute with competitor Axonics Inc. that has already lasted more than four years. The dispute centers on Medtronic’s InterStim device, an implanted ...
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics R20 ® ...
IRVINE, Calif.--(BUSINESS WIRE)-- Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...
Axonics, Inc. AXNX has received regulatory approval from the Therapeutic Goods Administration (TGA) to market its R20 rechargeable sacral neuromodulation (SNM) system in Australia. This cutting-edge ...
Even patent judges sometimes make mistakes. That is the oversimplified takeaway from a patent dispute between Axonics and Medtronic that has been anything but simple. The two companies have been ...
Axonics, Inc. (NASDAQ:AXNX) rose 1.5% in after-hours trading after a jury voted in its favor in a patent dispute with Medtronic (MDT). Medtronic (MDT) was seeking $150 million in a patent dispute with ...
The Federal Trade Commission (FTC) is taking a closer look at Boston Scientific’s $3.7 billion proposal to acquire neuromodulation developer Axonics, a move that could push back the closing of the ...
Never miss a trade again with the fastest news alerts in the world! This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday. Want the ...
It’s finally over. Medtronic and Boston Scientific’s Axonics longstanding patent battle is finished. The companies settled the legal spat over patent infringements related to sacral neuromodulation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results